Compare DexCom, Inc. (DXCM) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ross Stores, Inc. — how do they compare? DexCom, Inc. trades at $88.95 (market cap $33.79B), while Ross Stores, Inc. trades at $249.1 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 2.4× DexCom, Inc.'s market cap, and Ross Stores, Inc. pays a 0.71% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ROST | |
|---|---|---|
Market Cap | $33.79B | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $255.23 |
52-Week Low | $54.84 | $144.67 |
Enterprise Value | $33.24B | $81.37B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Ross Stores (ROST) trades at $254.83, near its consensus price target of $259.00, with a slight 0.16% decline. The stock shows strong fundamentals, including a 9.74% net income margin and 38.98% ROE for 2025, with recent quarterly earnings consistently beating estimates. Technical indicators are bullish, supported by positive moving averages and recent store expansion news.
The outlook remains positive due to robust earnings growth and analyst buy ratings (63.83% consensus). Key risks include high valuation multiples (P/E of 35.17) and competitive pressures in discount retail. Upside potential exists if Q2 2026 earnings beat expectations, but macroeconomic headwinds could pressure consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
